Mizuho lowered the firm’s price target on CoreWeave (CRWV) to $92 from $120 and keeps a Neutral rating on the shares. The firm adjusted targets in the software group as part of its 2026 outlook. The most important trends benefiting software vendors going forward are artificial intelligence, data modernization, DevOps, next-generation security, and electronic design automation, the analyst tells investors in a research note. Mizuho believes the low-teens median revenue growth forecast for 2026 “looks beatab ...

Atlanta, Georgia-based Assurant, Inc. (AIZ) provides protection services to connected devices, homes, and automobiles. Valued at $11.7 billion by market cap, the company offers mobile device solutions, extended service contracts, insurance products, vehicle protection, and housing-related coverage, including lender-placed, renters, and homeowners insurance. Companies worth $10 billion or more are generally described as “large-cap stocks,” and AIZ perfectly fits that description, with its market cap excee ...

This story was originally published on Manufacturing Dive. To receive daily news and insights, subscribe to our free daily Manufacturing Dive newsletter. Dive Brief: Manufacturers are planning to pass along cost increases and raise sales prices as input costs rise due to tariffs, according to the Institute for Supply Management’s December 2025 Supply Chain Planning Forecast published Tuesday. Among the manufacturing leaders surveyed for the forecast, 32% said they plan to pass on all of their tariff-re ...

Shares of Amazon.com Inc. (NASDAQ: AMZN) lost 2.66% over the past five trading sessions after losing 2.33% the five prior. ...

Arcus Biosciences (RCUS) entered late 2025 with growing optimism around its oncology pipeline, supported by encouraging clinical data, multiple upcoming catalysts, and a balance sheet strong enough to fund years of development. For a time, the company looked like a high-upside growth stock. However, that story was put to the test in December, when Arcus announced the cancellation of its Phase 3 STAR-221 research due to inefficiency. While the stock is up 49% year-to-date (YTD), it has plunged 16% from its ...

"We are pleased with the preliminary findings from our ongoing Phase 2a trial," stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. "The optimized gel formulation was designed to improve the patient experience, with both easier dispensation and skin application. The expansion of this psoriasis study continues our evaluation of synthetic hypericin into other disease indications, including non- orphan indications, where there remains an unmet medical need. Current estimates ...

"Our inclusion in the S&P MidCap 400 represents an important milestone for Corebridge, a recognition of both our commitment to growth and dedication to deliver for our customers,†said Marc Costantini, President and Chief Executive Officer. "With our robust product portfolio, strong distribution and disciplined risk management, we are well positioned to build upon this foundation to continue serving our customers, helping them meet their retirement and protection needs, while generating compelling value for ...

I have been working in the logistics sector for almost two decades. I have been into stock investing and macroeconomic analysis for almost a decade. Currently, I focus on ASEAN and NYSE/NASDAQ Stocks, particularly in banks, telco, logistics, and hotels. Since 2014, I have been trading on the PH stock market. I focus on banking, telco, and retail sectors. A colleague encouraged me to engage in the stock market as part of my portfolio diversification instead of putting all my savings in banks and properties. ...

DALLAS, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Beneficient (NASDAQ: BENF) (“Ben” or the “Company”), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets, today announced that its Board of Directors (the “Board”) has appointed Peter T. Cangany Jr. as Chairman of the Board, effective December 15, 2025. Mr. Cangany has served as a director of Beneficient and as Chairman of its independent Audit Committee sinc ...

Approval Triggers Milestone Payment of $7.5 Million from Sanofi; Cytokinetics Eligible to Receive Additional Milestone Payments and Royalties on Net Sales in Greater China SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that MYQORZO® (aficamten) has been approved by the China National Medical Products Administration (NMPA) for the treatment of adults with New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyo ...